Published in Blood on February 03, 2005
Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A (2007) 3.41
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood (2005) 2.06
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle (2009) 1.52
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res (2010) 1.18
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica (2010) 1.17
Apoptotic regulation by MCL-1 through heterodimerization. J Biol Chem (2010) 1.02
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood (2010) 1.02
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS One (2014) 0.92
Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway. J Cell Physiol (2012) 0.92
Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci (2009) 0.92
Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma (2013) 0.89
Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue. J Med Chem (2009) 0.86
Transcription inhibition as a therapeutic target for cancer. Cancers (Basel) (2011) 0.84
Heterodimerization of BAK and MCL-1 activated by detergent micelles. J Biol Chem (2010) 0.83
Particled Mica, STB-HO has chemopreventive potential via G1 arrest, and inhibition of proliferation and vascular endothelial growth factor receptor 2 in HCT colorectal cancer cells. BMC Complement Altern Med (2013) 0.79
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair. Mol Cancer (2010) 0.78
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC Pharmacol Toxicol (2013) 0.78
Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases. Cancer Biol Ther (2012) 0.77
Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts. PLoS One (2012) 0.77
The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function. Cell Death Dis (2014) 0.75
Roscovitine suppresses CD4+ T cells and T cell-mediated experimental uveitis. PLoS One (2013) 0.75
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS One (2016) 0.75
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. Haematologica (2010) 0.75
Application of new drugs in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2010) 0.75
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine. Sultan Qaboos Univ Med J (2011) 0.75
International network of cancer genome projects. Nature (2010) 20.35
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature (2003) 6.81
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell (2009) 5.96
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med (2009) 4.96
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell (2004) 4.46
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol (2005) 4.27
Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol (2002) 4.25
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer (2007) 3.16
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood (2008) 2.88
Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells. J Cell Biol (2005) 2.64
Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol (2011) 2.57
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol (2004) 2.55
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med (2005) 2.54
The role of mutant p53 in human cancer. J Pathol (2010) 2.49
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol (2013) 2.16
Specific recruitment of human cohesin to laser-induced DNA damage. J Biol Chem (2002) 2.13
The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J (2005) 2.12
Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer (2004) 2.10
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood (2010) 2.09
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol (2003) 1.97
Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene (2002) 1.91
The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4. DNA Repair (Amst) (2004) 1.86
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer (2002) 1.84
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol (2007) 1.82
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood (2005) 1.81
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci U S A (2007) 1.79
Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol (2004) 1.75
Cardiovascular GO annotation initiative year 1 report: why cardiovascular GO? Proteomics (2008) 1.72
The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood (2003) 1.70
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol (2007) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (2009) 1.64
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood (2005) 1.58
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum (2007) 1.54
PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53
Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. Mol Cell (2012) 1.50
Ubiquitination of HEXIM1 by HDM2. Cell Cycle (2009) 1.46
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem (2008) 1.43
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96. J Immunol (2011) 1.42
Transcriptional instability during evolving sepsis may limit biomarker based risk stratification. PLoS One (2013) 1.41
Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis (2002) 1.40
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol (2012) 1.36
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem (2010) 1.32
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood (2007) 1.32
Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis (2011) 1.31
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov (2008) 1.30
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res (2011) 1.29
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol (2008) 1.29
Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle (2007) 1.28
Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet (2013) 1.27
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep (2008) 1.25
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell (2013) 1.23
T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol (2007) 1.23
Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol (2005) 1.22
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle (2007) 1.22
Prox1 maintains muscle structure and growth in the developing heart. Development (2008) 1.21
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Up-regulation of Hlx in immature Th cells induces IFN-gamma expression. J Immunol (2004) 1.18
Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem (2004) 1.17
Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation. Proc Natl Acad Sci U S A (2010) 1.17
Delineation of the role of the Mre11 complex in class switch recombination. J Biol Chem (2004) 1.16
Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc (2008) 1.16
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood (2012) 1.14
Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol (2012) 1.14